Episode 18 - EXTRA Bonus Episode! Chronic Pain Management Part I - Regenerative Medicine, featuring our SPECIAL GUEST, RUSSELL CHANDLER!

1.The GP hook

Platelet-rich plasma and mesenchymal stem cells aren’t hype—they’re now part of day-to-day chronic pain care. Russell Chandler joins Brendan and Charlotte to unpack what GPs need to know.

Platelet-rich plasma and mesenchymal stem cells: not just hype anymore — but not a magic wand either. Russell Chandler (Greenside Referrals) joins Brendan and Charlotte to unpack what vets in the UK should actually know when clients ask about “stem cells for arthritis.”

You’re mid-consult and the owner asks, “What about stem cells? AI says it’ll fix everything.” Don’t wince — lean in. Here’s a practical, GP-focused summary of what Russell explained: the biology, the real-world pathway, who to consider referring, what you can reasonably do in practice, and the pitfalls to avoid.

2.Orthobiologics in a nutshell

Clinical pearl

Combining PRP with MSCs is common in referral settings. PRP supplies growth factors and forms a fibrin mesh; MSCs attach to 3‑D scaffold-like structures and may be retained locally for longer.

• Orthobiologics = biological products used to treat musculoskeletal disease.
• PRP (platelet‑rich plasma): autologous platelets concentrated and re‑suspended in the patient’s plasma. Prepared patient‑side with a centrifuge and consumables.
• MSCs (mesenchymal stem cells): multipotent cells with regenerative, immunomodulatory and anti‑inflammatory properties—commonly derived from adipose tissue in veterinary practice.
• Why different: most standard OA care is symptom‑modifying (analgesia, weight loss, physio, supplements). Orthobiologics aim to influence joint biology and slow progression — i.e. disease‑modifying potential rather than just palliation. That said, outcomes vary and careful diagnosis + targeting strongly influence results.
• Practical nuance: regenerative approaches are increasingly available in referral and larger practices. PRP is the most approachable entry‑level technique for general practice with training and QA; advanced MSC protocols are commonly performed in specialist centres.

3.PRP (platelet‑rich plasma) — practical points

Monday‑Morning move

• What it is: concentrated platelets that release a rich cocktail of growth factors when activated. These factors stimulate local healing pathways.
• How it’s made: take the patient’s blood, centrifuge using a validated system, concentrate the platelets and re‑suspend in plasma. Many commercial kits exist; supplier training matters.
• Quality control: check the concentrate on your haematology analyser before injection to confirm platelet concentration.
• Uses: intra‑articular injections, tendon and muscle injections, and PRP can be formed into a gel for application at fracture or oral/maxillofacial sites.
• GP entry point: PRP can be performed in‑practice if you have training, a validated centrifuge/kit, sterile technique, and the ability to perform accurate joint/tendon injections (ideally under US guidance).
• Add a “Regenerative medicine?” tick‑box to your OA consult template so you can start the conversation and triage cases for referral or in‑house PRP.

4.Mesenchymal stem cells — source and pathway

Timing & duration (as discussed)

• Typical source in Russell’s practice: falciform (midline) adipose tissue harvested by a small, aseptic laparotomy.
• Why fat? The adipose capillary bed contains pericytes (MSCs) in their biological niche — fat is biologically active, not just inert tissue.
• Processing: the harvested fat is shipped to a specialist cell lab where digestion, culture and passaging produce a viable MSC population. Russell described a turnaround of ≈4 weeks; the lab returns an implantable vial and cryo‑stores additional cells for future use.
• Implantation: cells are mixed with fresh PRP at the time of injection and implanted under sedation into joints/tendons/muscles. A second implantation is commonly performed about three months later. Storage allows later re‑injection without repeat harvest.
• Practical note: the falciform harvest is a small additional procedure; multimodal analgesia and local blocks make it well tolerated compared with major orthopaedic surgeries.
• MSC processing: typically around four weeks from harvest to return of cultured cells.
• Repeat implantation: commonly at ~3 months.
• Typical duration of benefit reported in Russell’s experience: many months, often around 18 months — patients are followed and re‑treated from cryo‑stored cells as needed.

5.Diagnose everything that might be painful — not just the obvious joint

Common trap

Treating the obvious arthritic joint only. Shoulder PDs commonly coexist with elbow OA (“shelbo”): if you don’t look, you won’t find the other pain generators and overall outcomes will be blunted.

• Russell emphasises a whole‑patient, data‑rich approach: stance analysis, force‑plate when available, goniometry, full orthopaedic exam and targeted imaging.
• Radiography is essential for joints. Musculoskeletal ultrasound (MSK US) is the other half of the picture — it finds soft‑tissue pain generators (biceps/supraspinatus enthesiopathies, iliopsoas strain) and allows precise, real‑time guided injections.
• Time is required. Proper MSK workups take longer than a 10–15 minute slot — that’s one reason complex cases are referred.

6.Who to refer, when — and what owners should expect

Owner conversation (phrase to reuse)

“Standard OA care eases symptoms; regenerative medicine aims to improve joint biology. We’d examine your dog nose‑to‑tail, target every painful area we find, and use your dog’s own biology (PRP ± stem cells). Results often last many months, and we can re‑inject using stored cells if needed.”

• Typical indications seen by Russell:
• Osteoarthritis (main indication).
• Tendinopathies, muscle or ligament problems and post‑operative situations (e.g. PRP at the time of cruciate repair).
• Younger patients with early OA — earlier intervention can change disease trajectory more than waiting for end‑stage disease.
• Referral expectations: a thorough whole‑animal diagnostic package, targeted orthobiologic implantation (PRP ± MSCs), cryo‑storage of cells, and structured follow‑up with re‑injection when scores slip.
• Outcomes: in Russell’s experience outcomes are generally good when diagnosis is comprehensive and targeting is accurate. He referenced a retrospective dataset (Armitage A., 2023; ~245 refractory OA cases) showing improvement across measured parameters — consider this descriptive evidence and search the literature for the primary paper for details.

7.What GPs can reasonably start doing now

Quick checklist before offering PRP in practice

Costs — be pragmatic

• Learn PRP: patient‑side PRP is a realistic first step if you invest in training, a validated kit/centrifuge and rigorous aseptic technique.
• Prioritise joint injection skills and build relationships with local MSK US operators or referral centres for guided injections.
• Always verify PRP platelet concentration on a haematology analyser as part of QA.
• When to refer:
• Young patients with early OA where disease‑modifying care may alter trajectory.
• Complex, multi‑site pain needing MSK US and a team approach.
• Owners who ask specifically for stem cells and accept the diagnostic workup and costs.
• Validated kit + training from supplier.
• Ability to confirm platelet concentration on your haematology analyser.
• Watertight asepsis from blood draw to injection.
• Confidence with joint/tendon injections or a named local partner for US guidance.
• Russell described tiered packages for comprehensive diagnostic + orthobiologic plans in the region of approximately £6,000–£8,000 (GBP) depending on how many cells are cultured and the extent of the plan; PRP‑only is less expensive. Treat these as indicative price ranges — always confirm current pricing and currency with the receiving clinic before quoting to owners.

8.Beyond joints — what’s being explored

• MSCs are being investigated in other inflammatory/immunomodulatory conditions (e.g. stomatitis complex, inflammatory bowel disease, anal furunculosis, renal disease) — many of these uses remain experimental and should be discussed as emerging areas unless you have robust local data.
• Future avenues discussed: use of exosomes (cell products) and cell modifications; these are active research topics.

9.Practical resources & contacts

• Greenside Referrals (Russell’s clinic): they accept regenerative referrals and can advise — contact details are available via their website; the clinic welcomes veterinary enquiries for case advice and referrals.
• Cell processing lab referenced: Cell Therapy Sciences (Coventry) — local specialist labs perform digestion, culture and cryo‑storage for autologous adipose MSC workflows.
• For further reading: see the retrospective case series led by Andy Armitage (circa 2023) describing outcomes in a cohort of refractory OA patients treated with orthobiologics — search for “Armitage 2023 orthobiologics retrospective” to locate the primary report.
• Russell has also written a practical manual on veterinary regenerative medicine (designed as a digestible, practice‑focused guide) — search for Russell Chandler regenerative medicine manual or check Greenside Referrals resources.

10.Take‑home points

Final word

Clients are already asking. Take a moment to familiarise yourself with PRP basics, know when to refer, and have a clear, honest owner conversation. That turns “airy‑fairy” into practical, evidence‑informed options for dogs with chronic musculoskeletal pain.

• Orthobiologics (PRP and adipose‑derived MSCs) are practical tools for musculoskeletal disease in referral contexts; PRP is an achievable in‑practice entry point with the right training and QA.
• PRP is autologous and patient‑side; MSCs typically require adipose harvest + specialist lab culture (turnaround ≈4 weeks) with injections often repeated at ~3 months and benefits commonly lasting many months (often ~18 months in reported experience).
• Outcomes depend heavily on whole‑patient diagnosis and precise targeting — MSK ultrasound and a thorough orthopaedic workup improve results.
• Earlier referral/intervention often gives better long‑term outcomes than waiting for end‑stage disease.
• Be transparent with clients about costs, timelines and the evidence: regenerative medicine is promising and increasingly used, but it’s not a magic cure — it's another tool in the chronic pain toolkit.